27. The method of claim 26, wherein the cell is contacted with the composition *in vivo*.

28. (Canceled) ~~The method of claim 26, wherein the inhibited p30 polypeptide-mediated cellular response comprises inhibition of a lymphocyte cellular response.~~

29. (Canceled) ~~The method of claim 28, wherein the inhibited lymphocyte response is lymphocyte proliferation.~~

30. (Canceled) ~~The method of claim 28, wherein the inhibited lymphocyte is a pathogenic effector cell.~~

31. (Canceled) ~~The method of claim 28, wherein the inhibited lymphocyte response modulates a T or a B lymphoma or leukemia or an autoimmune disease.~~

32. (Canceled) ~~The method of claim 31, wherein the autoimmune disease is rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus or myasthenia gravis.~~

34. (Canceled) ~~The method of claim 26, wherein the contacted cell expresses HVEM and the composition is a soluble p30 polypeptide.~~

35. (Canceled) ~~The method of claim 26, wherein the contacted cell expresses LTβR and the composition is a soluble p30 polypeptide.~~

36. (Amended) The method of claim 26, wherein the contacted cell expresses p30 polypeptide on its cell surface and the [composition] <u>HVEM polypeptide</u> is a soluble HVEM polypeptide.

51. (Amended) The method of claim 26, wherein the [composition] <u>HVEM or LTβR</u> that binds to a p30 polypeptide[, HVEM or LTβR is an antibody;] <u>comprises</u> a fusion protein comprising [p30 polypeptide,] HVEM or LTβR; or a functional fragment of [p30 polypeptide,] HVEM or LTβR.

52. (Amended) The method of claim 26, wherein the [composition] <u>HVEM or LTβR</u> that binds to a p30 polypeptide[, or HVEM or LTβR] is selected from soluble [HSV gD-1, gD-1 (Δ290-299t),] HVEM:Fc <u>or</u>, LTβR:Fc[, or LIGHT-t66].

Please add the following new claim:

--53. (New) A method for inhibiting a p30 polypeptide-mediated cellular response comprising

(a) providing a composition comprising an HVEM or LTβR polypeptide that binds to a p30 polypeptide and that inhibits binding of a cell surface expressed p30